Pembrolizumab Approved in Metastatic Small Cell Lung Cancer

Pembrolizumab (Keytruda®, Merck) has received accelerated FDA approval for patients with metastatic small cell lung cancer (SCLC) experiencing disease progression during or after platinum-based chemotherapy following at least one other previous line of therapy. Metastatic SCLC, or extensive-stage SCLC, comprises around 15% of all lung cancers and occurs primarily in heavy smokers. It carries a dismal outlook; only 5% of patients with extensive-stage SCLC live for two years after diagnosis. Appro...
Continue reading

Overall Survival for Pembrolizumab in Advanced NSCLC: Edward B. Garon, MD

Non-small cell lung cancer (NSCLC) has traditionally had a poor prognosis in terms of overall survival. This dismal outcome is changing, however: the phase 1 KEYNOTE-001 study found that pembrolizumab (Keytruda®, Merck) substantially increases five-year overall survival for patients with advanced NSCLC. In this interview with i3 Health, Edward B. Garon, MD, the study's lead investigator, discusses the trial's results and their implications for patients and physicians. Can you comment on the sign...
Continue reading

Advanced NSCLC: Pembrolizumab Increases Five-Year Survival

​ The phase I KEYNOTE-001 study reports that in patients with advanced non-small cell lung cancer (NSCLC), pembrolizumab (Keytruda®, Merck) increases five-year overall survival. "For patients with non-small cell lung cancer (NSCLC), median overall survival… and five-year survival rates have historically been poor," Edward B. Garon, MD, MS, Health Sciences Associate Clinical Professor of Medicine at the University of California, Los Angeles (UCLA), and colleagues comment in their publication in t...
Continue reading

Lifetime Brain Metastasis Risk in Older Patients With Cancer

Older adults with lung, breast, and skin cancers have an increased risk of developing brain metastasis during their lifetime. But how big is this risk? In an effort to find out, researchers used data from the Surveillance, Epidemiology, and End Results (SEER) Program on patients with lung cancer, breast cancer, or melanoma diagnosed with a brain metastasis, either one identified during primary cancer staging workup, called a synchronous brain metastasis (SBM), or one detected later in life, call...
Continue reading

New Biomarkers Could Help Prevent Lung Cancer

Lung cancer is the deadliest of all cancers; every year, 160,000 people die from it in the United States alone. Bronchial premalignant lesions (PMLs), precursors of lung squamous cell carcinoma, could contain biomarkers crucial to the prediction of this disease. Until recently, scientists lacked the knowledge to identify and treat distinct molecular types of PMLs. Now, researchers have identified four molecular subtypes of PMLs. These subtypes could pave the way to preventative therapies for ind...
Continue reading

© Copyright 2019 i3 Health. All rights reserved.